Navin Fluorine Q3 Results: Navin Fluorine International announced its results for the quarter ending December 2025 (Q3FY26) on February 2. The company posted a strong set of financial numbers, posting ...
HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy's laboratories aims to launch a generic version of Novo Nordisk's blockbuster weight loss drug Wegovy, subject to approval, at a price ...
India's Dr Reddy's Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed ...
WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...
The Supreme Court on Tuesday dismissed appeals in the 2002 death case of actress Prathyusha, ruling out murder and affirming Gudipalli Siddhartha Reddy’s conviction for abetment of suicide. Reddy ...
HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories (REDY.NS), opens new tab hopes to launch a generic version of Novo Nordisk’s (NOVOb.CO), opens new tab blockbuster weight‑loss ...
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, ...
HYDERABAD, (IANS) – In a setback for Jhansi Reddy, a member of the Congress party, her application for Indian citizenship has been denied by Indian authorities. Jhansi Reddy, who holds American ...
Feb 18 (Reuters) - India's Stable Money has raised $25 million in a round led by Peak XV Partners, as the fixed-income investment platform aims to triple its assets under management by year-end to 150 ...
Navin Fluorine International Limited was incorporated on June 25, 1998. AS a flagship, Company belongs to a reputed industrial house of Padmanabh Mafatlal Group in India. It has largest integrated ...
Sumathi Reddy is the "Your Health" columnist at The Wall Street Journal, writing about all things health and medicine. Her columns cover everything from exercise and weight-loss drugs to cannabis and ...
Citi maintained a sell rating and raised its target price to Rs 5,550 from Rs 4,900. It noted that EBITDA rose 110 per cent year-on-year and margins improved sharply, but said the stock’s recent rally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results